Quick Answer
Onconetix, Inc. reported Earnings Per Share Diluted of $16.56 (loss) per share for the year ending 2025.
- Onconetix, Inc. showed an increase of +99.1% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Onconetix, Inc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $0.29 (loss) per share | Q3 2021: $0.40 (loss) per share | Q1 2022: $0.34 (loss) per share | Q2 2022: $0.36 (loss) per share | Q3 2022: $0.27 (loss) per share | Q1 2023: $0.18 (loss) per share | Q2 2023: $0.43 (loss) per share | Q3 2023: $12.21 (loss) per share | Q1 2024: $20.08 (loss) per share | Q2 2024: $2,191.59 (loss) per share | Q3 2024: $249.08 (loss) per share | Q1 2025: $0.53 (loss) per share | Q2 2025: $4.76 (loss) per share | Q3 2025: $6.25 (loss) per share.
- Over the full 5 years of available data (2021 to 2025), Onconetix, Inc.'s Earnings Per Share Diluted has declined by 1,214.3%.
- Historical annual values: Fiscal year 2025: $16.56 (loss) per share | Fiscal year 2024: $1,823.39 (loss) per share | Fiscal year 2023: $87.45 (loss) per share | Fiscal year 2022: $1.10 (loss) per share | Fiscal year 2021: $1.26 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: